Liminatus Pharma, Earnings Estimate
Liminatus Pharma, Earnings per Share Projection vs Actual
About Liminatus Pharma, Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Liminatus Pharma, earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Liminatus Pharma, estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Liminatus Pharma, fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -17.5 M | -18.4 M | |
| Earnings Yield | (0.08) | (0.08) | |
| Price Earnings Ratio | (12.41) | (13.03) | |
| Price Earnings To Growth Ratio | (0.07) | (0.08) |
Pair Trading with Liminatus Pharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Liminatus Pharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Liminatus Pharma, will appreciate offsetting losses from the drop in the long position's value.Moving together with Liminatus Stock
Moving against Liminatus Stock
| 0.83 | REGN | Regeneron Pharmaceuticals | PairCorr |
| 0.82 | VRTX | Vertex Pharmaceuticals | PairCorr |
| 0.77 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.71 | ARGX | argenx NV ADR | PairCorr |
| 0.67 | SHG | Shinhan Financial | PairCorr |
The ability to find closely correlated positions to Liminatus Pharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Liminatus Pharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Liminatus Pharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Liminatus Pharma, Class to buy it.
The correlation of Liminatus Pharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Liminatus Pharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Liminatus Pharma, Class moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Liminatus Pharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Liminatus Pharma, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Liminatus Pharma,. If investors know Liminatus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Liminatus Pharma, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.16) |
The market value of Liminatus Pharma, Class is measured differently than its book value, which is the value of Liminatus that is recorded on the company's balance sheet. Investors also form their own opinion of Liminatus Pharma,'s value that differs from its market value or its book value, called intrinsic value, which is Liminatus Pharma,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Liminatus Pharma,'s market value can be influenced by many factors that don't directly affect Liminatus Pharma,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Liminatus Pharma,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Liminatus Pharma, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Liminatus Pharma,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.